Literature DB >> 35220647

Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with protease inhibitors-based direct-acting antivirals?

Yu Jun Wong1,2, Mindie H Nguyen3,4.   

Abstract

Entities:  

Keywords:  effectiveness; real-world; tolerability; treatment outcome

Mesh：

Substances：

Year:  2022        PMID： 35220647     DOI： 10.1111/liv.15214

Source DB:  PubMed          Journal:  Liver Int        ISSN： 1478-3223            Impact factor:   5.828


× No keyword cloud information.
  1 in total

1.  Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: Real-world data from a multicenter Asian registry.

Authors:  Y J Wong; R Kumar; R Kumar; J Tan; C H Liu; Vw-K Hui; S S Tan; J H Kao; Gl-H Wong; P H Thurairajah
Journal:  J Gastroenterol Hepatol       Date:  2022-06-30       Impact factor: 4.369
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.